CY1107997T1 - Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης - Google Patents

Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης

Info

Publication number
CY1107997T1
CY1107997T1 CY20071100121T CY071100121T CY1107997T1 CY 1107997 T1 CY1107997 T1 CY 1107997T1 CY 20071100121 T CY20071100121 T CY 20071100121T CY 071100121 T CY071100121 T CY 071100121T CY 1107997 T1 CY1107997 T1 CY 1107997T1
Authority
CY
Cyprus
Prior art keywords
dementia
syndrome
prevention
treatment
novel methods
Prior art date
Application number
CY20071100121T
Other languages
Greek (el)
English (en)
Inventor
Raymond Pratt
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1107997T1 publication Critical patent/CY1107997T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CY20071100121T 2000-03-03 2007-01-29 Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης CY1107997T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18674400P 2000-03-03 2000-03-03
US19761000P 2000-04-18 2000-04-18
US22078300P 2000-07-25 2000-07-25
US25922601P 2001-01-03 2001-01-03
EP01922272A EP1311272B1 (en) 2000-03-03 2001-03-05 Novel methods using cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
CY1107997T1 true CY1107997T1 (el) 2013-09-04

Family

ID=27497683

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100121T CY1107997T1 (el) 2000-03-03 2007-01-29 Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης

Country Status (11)

Country Link
US (7) US20020035128A1 (US06576646-20030610-C00016.png)
EP (5) EP2140868A1 (US06576646-20030610-C00016.png)
JP (1) JP2003525903A (US06576646-20030610-C00016.png)
AT (1) ATE345803T1 (US06576646-20030610-C00016.png)
AU (1) AU2001249091A1 (US06576646-20030610-C00016.png)
CY (1) CY1107997T1 (US06576646-20030610-C00016.png)
DE (1) DE60124730T2 (US06576646-20030610-C00016.png)
DK (1) DK1311272T3 (US06576646-20030610-C00016.png)
ES (1) ES2275670T3 (US06576646-20030610-C00016.png)
PT (1) PT1311272E (US06576646-20030610-C00016.png)
WO (1) WO2001066114A1 (US06576646-20030610-C00016.png)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
PT1311272E (pt) * 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
AU2002245692A1 (en) * 2001-03-15 2002-10-03 David Pharmaceuticals Methods for restoring cognitive function following systemic stress
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
JPWO2003061658A1 (ja) * 2002-01-22 2005-05-19 エーザイ株式会社 インダノン誘導体を含有するシグマ受容体結合剤
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US20060129385A1 (en) * 2002-07-22 2006-06-15 Heller James H Cholinergic therapy for individuals with learning disabilities
AU2003287433A1 (en) * 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
CA2516618A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
US7723349B2 (en) 2003-04-24 2010-05-25 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) * 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
CA2567746A1 (en) * 2003-05-23 2005-01-06 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment and improving cognition
JP4137159B2 (ja) 2003-06-17 2008-08-20 ファイザー・インク セロトニン及びノルアドレナリン再取り込み阻害薬としてのｎ−ピロリジン−３−イル−アミド誘導体
US20070054940A1 (en) * 2003-09-19 2007-03-08 Eisai Co., Ltd. Remedy for down's syndrome
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
EP1743036A4 (en) * 2004-01-22 2008-07-02 Genaissance Pharmaceuticals APOE GENERAL MARKERS RELATED TO ALZHEIMER IN THE FIRST EARLY PERIOD
AU2005208871B2 (en) * 2004-01-26 2010-04-01 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
EP1718294A4 (en) * 2004-01-30 2007-10-03 Axonyx Inc METHODS OF TREATING COMPLICATIONS OF DIABETES
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20060135507A1 (en) * 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
US20060079558A1 (en) * 2004-09-27 2006-04-13 Bridge Pharma. Inc. R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
WO2006036936A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
RS51822B (en) * 2005-04-04 2012-02-29 Eisai R. &D. Management Co. Ltd. DIHYDROPYRIDINE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND Dementia
GB0605544D0 (en) * 2006-03-20 2006-04-26 Univ Nottingham Genetic Markers For Alzheimer Disease
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
CA2655809C (en) * 2006-07-21 2013-10-01 Bridge Pharma, Inc. Dermal anesthetic compounds
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
US20080131491A1 (en) * 2006-12-01 2008-06-05 Akinori Hanatani Percutaneously absorbable preparation
EP2131828A2 (en) * 2007-03-05 2009-12-16 Eisai R&D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
JP2010524844A (ja) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 認知症のためのシンナミド化合物
JP2010526825A (ja) * 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
JP2011502966A (ja) * 2007-10-31 2011-01-27 アルセレス ファーマシューティカルズ， インコーポレイテッド ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法
US20090156561A1 (en) * 2007-12-13 2009-06-18 Seed John C Use of Cholinesterase Inhibitors In Smoking Cessation
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2009145177A1 (ja) * 2008-05-30 2009-12-03 日東電工株式会社 ドネペジル含有貼付製剤およびその包装体
CN102046171B (zh) * 2008-05-30 2013-06-19 日东电工株式会社 经皮吸收制剂
BRPI0917862A2 (pt) * 2008-09-30 2015-11-24 Teikoku Pharma Usa Inc composições transdérmicas de donepezil com distribuição prolongada e métodos para usar as mesmas
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
BRPI0920927A2 (pt) * 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
JP2012523437A (ja) * 2009-04-13 2012-10-04 セラヴァンス， インコーポレーテッド 認知障害の治療のための５−ｈｔ４受容体アゴニスト化合物
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
GR1007368B (el) 2010-05-27 2011-08-02 Alapis Α.Β.Ε.Ε., Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
US9265738B2 (en) 2012-01-20 2016-02-23 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in demyelinating disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US9359315B2 (en) * 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
WO2015168286A1 (en) 2014-04-30 2015-11-05 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3334425B1 (en) * 2015-08-14 2020-12-16 QR Pharma Methods of treatment or prevention of acute brain or nerve injuries
CA3083015A1 (en) 2017-05-24 2018-11-28 Qr Pharma, Inc. Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans
AU2018360730A1 (en) 2017-10-30 2020-05-21 Montreal Heart Institute Methods of treating elevated plasma cholesterol
CA3146794A1 (en) * 2019-07-16 2021-01-21 Rush University Medical Center Use of a benzoate containing composition to treat neurodegenerative disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2777159B2 (ja) * 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
JP3075566B2 (ja) 1990-05-15 2000-08-14 エーザイ株式会社 光学活性インダノン誘導体
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
AU665207B2 (en) * 1991-07-29 1995-12-21 Warner-Lambert Company Quinazoline derivatives as acetylcholinesterase inhibitors
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
CA2252806C (en) 1996-06-07 2005-11-22 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
ATE241358T1 (de) 1997-03-03 2003-06-15 Eisai Co Ltd Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
AU9454098A (en) * 1997-09-24 1999-04-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
ATE260896T1 (de) 1997-12-05 2004-03-15 Eisai Co Ltd Donepezil polykristalle und verfharen zu ihrer herstellung
DE69924467T2 (de) 1998-01-16 2006-02-16 Eisai Co., Ltd. Verfahren zur herstellung von donepezilderivaten
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
KR100801236B1 (ko) 1998-08-28 2008-02-11 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
WO2000059544A1 (fr) 1999-03-31 2000-10-12 Eisai Co., Ltd. Compositions stabilisees contenant des medicaments nootropes
PT1311272E (pt) * 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2003092606A2 (en) 2002-05-01 2003-11-13 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
AU2003287433A1 (en) * 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil

Also Published As

Publication number Publication date
US20020035129A1 (en) 2002-03-21
EP1311272B1 (en) 2006-11-22
US20020035128A1 (en) 2002-03-21
WO2001066114A1 (en) 2001-09-13
US6458807B1 (en) 2002-10-01
AU2001249091A1 (en) 2001-09-17
EP1311272A4 (en) 2003-05-21
DK1311272T3 (da) 2007-02-26
PT1311272E (pt) 2007-02-28
US20040122051A1 (en) 2004-06-24
US6576646B1 (en) 2003-06-10
ATE345803T1 (de) 2006-12-15
US20050250812A1 (en) 2005-11-10
EP1311272A1 (en) 2003-05-21
EP2138177A1 (en) 2009-12-30
DE60124730D1 (de) 2007-01-04
EP2140868A1 (en) 2010-01-06
EP2133078A1 (en) 2009-12-16
US7563808B2 (en) 2009-07-21
DE60124730T2 (de) 2007-10-04
US20020040038A1 (en) 2002-04-04
JP2003525903A (ja) 2003-09-02
US6689795B2 (en) 2004-02-10
US6482838B2 (en) 2002-11-19
ES2275670T3 (es) 2007-06-16
EP2130538A1 (en) 2009-12-09
US20030040532A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
CY1107997T1 (el) Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
RU98114683A (ru) Производные 5-н-тиазол[3,2-a]пиримидина
WO2003051315A3 (en) Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
CY1105507T1 (el) Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
TR199902291T2 (xx) �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
HK1050894A1 (en) Aryl fused azapolycyclic compounds
MY117896A (en) Quinazoline derivatives
CA2170700A1 (en) Pyrazolopyrimidines and Pyrrolopyrimidines for Treatment of Neuronal and Other Disorders
DE60336890D1 (de) Kondensierte pyridazinderivat-verbindungen und die verbindungen als wirkstoff enthaltende arzneimittel
CA2339008A1 (en) Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
TW200505907A (en) Piperidine-benzenesulfonamide derivatives
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
PT912184E (pt) Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
MY124786A (en) Bis-arylsulfones
RU2003128982A (ru) Карбаматы для предотвращения или лечения нейродегенеративных нарушений
YU12003A (sh) Novi derivati aminocikloheksana
BG103252A (en) The use of benzopyranols for the treatment of neurological disorders
AR022083A1 (es) Derivados de piperidina
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders
PT1334094E (pt) Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol